<DOC>
	<DOCNO>NCT00505661</DOCNO>
	<brief_summary>Primary Objectives : - To determine objective response rate Letrozole administer patient advanced recurrent borderline tumor low-grade epithelial cancer ovary , fallopian tube peritoneum . - To determine time tumor progression patient advance recurrent borderline tumor low-grade epithelial cancer ovary , fallopian tube peritoneum . - To identify biological marker predict response Letrozole study aspect hormones type tumor .</brief_summary>
	<brief_title>Letrozole Patients With Ovarian Tumors</brief_title>
	<detailed_description>Letrozole anticancer hormone FDA approve use patient advance breast cancer . Before enrolled study , must go screening test make sure eligible . The screening test include complete medical history physical exam , include measurement pulse rate , breathe rate , temperature , height , weight , blood pressure . The physical examination also include measurement visible cancer lesion . You ask medication take , include counter medication , herbal medication , vitamin . You chest x-rays and/or CT MRI scan measure size tumor . You routine blood test ( 2 1/2 tablespoon ) perform . If qualify study , take Letrozole day mouth . Letrozole dispense form tablet . Four eight week worth Letrozole prescribe treatment doctor visit . You continue receive Letrozole long respond treatment . You require come back check-up least every 2 month study first two year . You contact study doctor feel unwell feel need see doctor appointment earlier designate appointment . At follow-up visit , complete physical exam . The chest x-rays and/or CT MRI scan repeat every 2 month , time complete trial , time necessary . Blood test ( 1 tablespoon ) perform every 2 month . Information medication take , medical problem since last visit collect . At follow-up visit , also ask complete one page , paper pencil check sheet . You ask identify symptom may note amount distress symptom cause . You take study disease get bad intolerable side effect occur doctor discus possible treatment option . However , long continue benefit Letrozole treatment , continue treatment . If letrozole treatment beyond two year , follow three month interval . At follow visit , ask question medical history physical exam . You also blood ( tablespoon ) urine test , and/or radiological evaluation tumor . As long continue benefit letrozole treatment , follow . Your status follow long possible even take study drug . You contact phone ask come clinic routine visit . You contact every 6 week 1 year study every 12 week rest life . This investigational study . Letrozole approve FDA treatment recurrent low grade borderline ovarian , fallopian tube primary peritoneal cancer . A total 80 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Letrozole</mesh_term>
	<criteria>1 . History histologically confirm diagnosis borderline tumor lowgrade epithelial cancer ovary , fallopian tube primary peritoneum . Eligible histology include borderline serous papillary , borderline mucinous papillary , borderline endometrioid , lowgrade serous papillary , lowgrade mucinous papillary , lowgrade endometrioid mixture . Patients whose tumor histologically borderline low grade invasive implant also include . Patients whose tumor histologically borderline include high grade component exclude . 2 . Recurrent advance borderline lowgrade epithelial ovarian , fallopian tube primary peritoneal tumor amenable surgery , patient measurable residual disease end secondary cytoreduction . 3 . The ovarian tumor either estrogen receptor progesterone receptor positive . 4 . Measurable disease radiological imaging study . Raised CA125 tumor marker alone lesion locate previously irradiate area consider measurable . 5 . Age great 18 year age . 6 . Expected survival 12 week . 7 . Eastern Cooperative Oncology Group ( ECOG ) performance status 01 . 8 . Willingness comply study procedure follow examination . 9 . Have write informed consent . ( Signature consent form indicate patient aware nature disease willingly give write consent inform procedure follow , experimental nature therapy , alternative treatment option potential benefit risk associated therapy ) . 10 . Known history Central nervous system metastasis allow patient treatment , neurologically stable , require oral intravenous steroid anticonvulsant , provide brain scan ( Computer Assisted Tomography Magnetic Resonance Imaging Scans ) show absence active disease . 11 . Have adequate bone marrow reserve indicate absolute neutrophil count ( ANC ) &gt; 1,500/ mm3 ; platelet count &gt; 100,000/mm3 ; hemoglobin &gt; 9.0g/dL . 12 . Have adequate liver function test indicate bilirubin &lt; 1.5 X normal , alanine aminotransferase ( ALT ) &lt; 3 X normal ; aspartate aminotransferase ( AST ) &lt; 3 X normal . 13 . Have adequate renal function test indicate serum creatinine &lt; 1.5mg/dl . 1 . Failure recover prior surgery major surgery within 4 week study entry 2 . Patients sarcomatous , germ cell stromal element cancer eligible . 3 . Patients intermediate highgrade primary ovarian , fallopian tube , primary peritoneal epithelial carcinoma . Patients whose tumor histologically borderline include high grade component exclude . 4 . Pregnant lactate woman 5 . Leptomeningeal carcinomatous meningitis 6 . Unstable medical condition uncontrolled cardiac arrythmia history myocardial infarction within 6 month 7 . Any severe , concurrent disease , infection comorbidity , judgment investigator , would make patient inappropriate study entry . 8 . Any sign intestinal obstruction interfere nutrition 9 . Treatment chemotherapy , radiotherapy , radiopharmaceutical immunotherapy within 4 week first study dose letrozole ( within 6 week nitrosureas mitomycin C ) failure recover toxic effect therapies prior study entry . 10 . Patients 4 prior chemotherapy regime platinum regimes count one . 11 . Patients prior anticancer hormonal therapy ovarian cancer aromatase inhibitor . Patients treat gonadotrophin agonist , gonadotropin antagonist Selective estrogen receptor modulators ( SERMS ) allow . Patients hormone replacement therapy fertility treatment estrogens gonadotropin also allow . 12 . Patients estrogen progesterone replacement therapy must wash period 4 week . 13 . A history prior malignancy except adequately treat carcinoma situ cervix , basal cell squamous cell skin cancer , cancer patient disease free least five year 14 . Patients receive concurrent chemotherapy , radiotherapy immunotherapy . 15 . Participation investigational drug study within 30 day first day dose . 16 . Psychiatric disorder would preclude obtain informed consent participation ongoing research study 17 . Patients known history human immunodeficiency virus ( HIV ) infection 18 . Patients inadequately treat serious thromboembolic disease pulmonary embolism deep vein thrombosis , know clot disorder .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Ovarian Cancer</keyword>
	<keyword>Fallopian Tube Cancer</keyword>
	<keyword>Peritoneal Cancer</keyword>
	<keyword>Letrozole</keyword>
	<keyword>Femara</keyword>
</DOC>